SPL.AX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 14:10):

Stats
今日成交量	1.16M
平均成交量	381 673
市值	49.44M
EPS	$0 ( 2024-02-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.00
ATR14	$0.00200 (1.67%)

音量相关性

長: 0.09 (neutral)

短: 0.04 (neutral)

Signal:(53.313) Neutral

Starpharma Holdings Ltd 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Starpharma Holdings Ltd 相关性 - 货币/商品

-0.66
( moderate negative )

-0.79
( moderate negative )

0.00
( neutral )

0.72
( moderate )

Starpharma Holdings Ltd 财务报表

Annual	2023
营收:	$2.94M
毛利润:	$1.22M (41.60 %)
EPS:	$-0.0400

FY	2023
营收:	$2.94M
毛利润:	$1.22M (41.60 %)
EPS:	$-0.0400

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0

FY	2022
营收:	$4.68M
毛利润:	$1.91M (40.71 %)
EPS:	$-0.0400

Financial Reports:

No articles found.

Starpharma Holdings Ltd

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.